Gilde Healthcare leads $24 million financing round of respiratory care provider Vapotherm - Gilde Healthcare

Gilde Healthcare leads $24 million financing round of respiratory care provider Vapotherm

7 april 2014

EXETER, New Hampshire – Vapotherm, Inc. announced a $24MM financing round led by Gilde Healthcare. Adage Capital Management joined as new co-investor. The round was completed by existing investors Morgenthaler Ventures, Kaiser Permanente, 3×5 Special Opportunity Fund, Integral Capital Partners, QuestMark Partners and Cross Creek Capital.

Geoff Pardo, Partner of Gilde Healthcare joins as new member of the Board of Directors:

“Vapotherm’s unique respiratory solution has proven to generate superior patient outcomes and lower the cost of care for providers. We look forward to grow the company internationally and improve healthcare for patients world-wide.”

Vapotherm develops, manufactures and markets advanced respiratory care devices. The company sells innovative, comfortable, noninvasive technologies for respiratory support of patients with chronic or acute breathing disorders. Over 600,000 patients have been treated with Vapotherm’s proprietary high flow therapy. For more information, visit www.vtherm.com.

 

About Gilde Healthcare (www.gildehealthcare.com)

Gilde Healthcare (Utrecht, The Netherlands and Cambridge, Massachusetts) is a transatlantic growth capital investor focused on private healthcare companies. It has over €450 million ($600 million) under management and is actively looking to lead new investments in therapeutics, diagnostics, medical devices and healthcare services. For a list of Gilde’s portfolio companies please visit our new website at www.gildehealthcare.com.

Gilde Healthcare company Noema Pharma Announces First Patients Dosed in Phase 2b Study for Tourette Syndrome

Phase 2b study will evaluate the safety and efficacy of gemlapodect (NOE-105) in patients with Tourette syndrome Noema Pharma AG, a clinical-stage neuroscience-based company, today announced the first patients have been dosed in a global...
30 oktober 2024

Gilde Healthcare invests in SynOx Therapeutics and company doses first patients in Phase 3 trial

Gilde Healthcare Leads Series B Extension, Joining Premier Syndicate of Leading Life Science Investors Funding Supports Registrational Phase 3 TANGENT Trial of Emactuzumab, a Best-in-Class CSF-1 Receptor Targeted Antibody, for the Treatment of Tenosynovial Giant...
30 oktober 2024

Gilde Healthcare co-leads in an oversubscribed £80 million Series B financing in Purespring Therapeutics

Funds raised will support Purespring in advancing its AAV pipeline of gene therapy programmes to treat kidney disease, including its lead programme targeting IgA Nephropathy (IgAN) Round brings in new biotech investors, Gilde Healthcare, Sofinnova...
9 oktober 2024